Winst gevend schreef op 2 februari 2022 17:49:
This study was temporarily halted due to COVID-19 but has since resumed. Subject to COVID-19-related delays, data is expected in the first half of 2022, followed by review by regulatory authorities in the second half of 2022. If approved, the drug is planned to launch late 2022.
Is dus vandaag uitgesteld naar Q1 2023